Renaissance Technologies LLC Reduces Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Renaissance Technologies LLC lowered its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,079,400 shares of the company's stock after selling 139,400 shares during the period. Renaissance Technologies LLC owned about 0.10% of Takeda Pharmaceutical worth $40,771,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Versant Capital Management Inc bought a new position in shares of Takeda Pharmaceutical in the fourth quarter worth $26,000. Wilmington Savings Fund Society FSB acquired a new stake in Takeda Pharmaceutical in the third quarter valued at approximately $40,000. BNP Paribas Financial Markets grew its holdings in Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after purchasing an additional 2,596 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after buying an additional 1,976 shares during the last quarter. Finally, Crowley Wealth Management Inc. acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at about $52,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Trading Up 1.1 %

Shares of NYSE:TAK traded up $0.16 during midday trading on Wednesday, hitting $14.70. The company had a trading volume of 473,325 shares, compared to its average volume of 1,846,979. The firm has a fifty day simple moving average of $14.50 and a 200 day simple moving average of $13.90. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a market cap of $46.77 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 0.24 and a beta of 0.39. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.37.

Remove Ads

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.